Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly delays time to PSA progression compared to placebo plus ADT Study enrolled 180 men with metastatic hormone-sensitive prostate cancer in mainland China TOKYO, March 13, 2023 /PRNewswire/ — Astellas Pharma Inc….

Leave a Reply

Your email address will not be published. Required fields are marked *